EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Ovarian NeoplasmsPeritoneal NeoplasmsFallopian Tube Neoplasms
- Interventions
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2012-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT00035100
- Locations
- 🇬🇧
Novartis Investigative Site, Surrey, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath